Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemotherapy vs DCF in Neoadjuvant Treatment of Resectable Locally Advanced ESCC
NCT06952621Phase 3Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tangdu Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06952621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952621.